Friday, July 24 Company Presentations 6–Taiwan BIO Award Winners
Name /Yufeng Jane Tseng
Title /Founder and Scientific Advisor
Telephone /(Work) (886)-2-33664888#403
Yoda Pharmaceuticals Inc. is an innovative drug development company founded in 2019 in Taiwan. Partnering with international experts, Yoda utilizes state-of-the-art AI technology and big data to develop novel compounds in new drugs for unmet medical needs in neuropsychological diseases and neurological diseases. Yoda is committed to bring innovations and transform lives of patients – may the force be with all of us.
RS-D7 is a novel NCE, with positive clinical data in treating schizophrenia and multiple systems atrophy. RS-D7 was jointly developed by professors and psychiatrists from NTU, NTU Hospital, NHRI, and NCTU in Taiwan, and licensed exclusively to Yoda Pharmaceuticals Inc. in 2019. Yoda is seeking investment to complete IND-enabling studies, IND filing, and clinical trials to advance the development and approval of RS-D7.
As an efficacious NCE to treat negative and cognitive symptoms of schizophrenia, RS-D7 differs from antipsychotics approved to date, which focus solely on treatment of positive and mood-related symptoms. Clinical results from human studies indicate RS-D7 effectively improve patients’ verbal and visual memory and could potentially be used long-term, either alone or in combination with other CNS drugs.
In addition, RS-D7’s proof-of-concept clinical trial resulted in positive therapeutic effects on alleviation of ataxia-related motor deficits in mice, pointing to potential of it becoming the first-in-class drug to treat multiple systems astrophy (MSA). MSA with cerebellar ataxia is a progressive brain disorder affecting movement and balance and disrupts the autonomic nervous system. Treatment of MSA and ataxia is an unmet medical need as existing agents have shown no promising effect in relieving symptoms of ataxia and uncoordinated movements.
Name /Da-Zhong Luo